Olodaterol

Overview

Olodaterol (trade name Striverdi Respimat) is an ultra-long-acting β adrenoreceptor agonist (ultra-LABA) used as an inhalation for treating people with chronic obstructive pulmonary disease (COPD). It is manufactured by Boehringer Ingelheim.[1] WP

Uses, dosage and effects

Medical uses

Olodaterol is a once-daily maintenance bronchodilator treatment of airflow obstruction in people with COPD. While it appears to reduce COPD exacerbations it does not appear to alter the speed at which a person's lungs worsen or alter their life expectancy.[2] WP

As of December 2013, olodaterol is not approved as a treatment of asthma. It is administered in an inhaler called Respimat Soft Mist Inhaler. WP

Risks and side effects

Adverse effects

Adverse effects generally were rare and mild in clinical studies. Most common, but still affecting no more than 1% of patients, were nasopharyngitis (running nose), dizziness and rash. To judge from the drug's mechanism of action and from experiences with related drugs, hypertension (high blood pressure), tachycardia (fast heartbeat), hypokalemia (low blood levels of potassium), shaking, etc., might occur in some patients, but these effects have rarely, if at all, been observed in studies.[1] WP

Interactions

Interactions

Based on theoretical considerations, co-application of other beta-adrenoceptor agonists, potassium lowering drugs (e.g. corticosteroids, many diuretics, and theophylline), tricyclic antidepressants, and monoamine oxidase inhibitors could increase the likelihood of adverse effects to occur. Beta blockers, a group of drugs for the treatment of hypertension (high blood pressure) and various conditions of the heart, could reduce the efficacy of olodaterol. Clinical data on the relevance of such interactions are very limited.[1] WP

Pharmacology

Mechanism of action

Like all β adrenoreceptor agonists, olodaterol mimics the effect of epinephrine at β₂ receptors in the lung, which causes the bronchi to relax and reduces their resistance to airflow.[3] WP

Olodaterol is a nearly full β₂ agonist, having 88% intrinsic activity compared to the gold standard isoprenaline/isoproterenol). Its half maximal effective concentration (EC₅₀) is 0.1 nM. It has a higher in vitro selectivity for β₂ receptors than the related drugs formoterol and salmeterol: 241-fold versus β₁ and 2299-fold versus β₃ adrenergic receptors. The high β₂/β₁ selectivity may account for the apparent lack of tachycardia in clinical trials, which is mediated by β₁ receptors on the heart.[4] WP

Pharmacokinetics

Olodaterol is substantially metabolized by glucuronidation (UGT2B7, UGT1A1, UGT1A9) and O-demethylation (CYP2C8, CYP2C9).[5] WP

Pharmacodynamics

Once bound to a β₂ receptor, an olodaterol molecule stays there for hours — its dissociation half-life is 17.8 hours — which allows for once-a-day administration of the drug like with indacaterol. Other related compounds generally have a shorter duration of action and have to be administered twice daily (e.g., formoterol, salmeterol). Still others (e.g., salbutamol/albuterol, fenoterol) have to be used three or four times a day for continuous action, which may be an advantage for patients who need β₂ agonists only occasionally; for example, in an asthma attack.[3][6] WP

History

History

On 29 January 2013 the U.S. Food and Drug Administration (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) recommended that the clinical data included in the new drug application (NDA) for olodaterol provide substantial evidence of safety and efficacy to support the approval of olodaterol as a once-daily maintenance bronchodilator treatment for airflow obstruction in patients with COPD.[7] WP

On 18 October 2013 approval of olodaterol in the first three European countries — the United Kingdom, Denmark and Iceland — was announced by the manufacturer.[8] WP

On July 31, 2014 the U.S. Food and Drug Administration approved Striverdi Respimat (olodaterol inhalation spray) to treat patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema that are experiencing airflow obstruction.[9] WP

Chemistry

Formula

C21H26N2O5 PC

CAS number

868049-49-4 PC

Molar mass (g/mol)

386.4 PC

IUPAC name (computed by PubChem)

6-hydroxy-8-[(1R)-1-hydroxy-2-[[1-(4-methoxyphenyl)-2-methylpropan-2-yl]amino]ethyl]-4H-1,4-benzoxazin-3-one PC

SMILES

CC(C)(CC1=CC=C(C=C1)OC)NC[C@@H](C2=C3C(=CC(=C2)O)NC(=O)CO3)O PC

InChIKey

COUYJEVMBVSIHV-SFHVURJKSA-N PC

PubChem CID

11504295

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other Striverdi Drugs.com UK striverdi-respimat-2-5-microgram-solution-for-inhalation-leaflet
2. Journal / agency Melani, AS. Olodaterol for the treatment of chronic obstructive pulmonary disease: a narrative review. Expert Opinion on Pharmacotherapy. October 2018. doi:10.1080/14656566.2018.1518431 · PMID 30311516
3. Journal / agency Casarosa P, Kollak I, Kiechle T, Ostermann A, Schnapp A, Kiesling R, Pieper M, Sieger P, Gantner F. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol. The Journal of Pharmacology and Experimental Therapeutics. June 2011. doi:10.1124/jpet.111.179259 · PMID 21357659
4. Journal / agency Bouyssou T, Casarosa P, Naline E, Pestel S, Konetzki I, Devillier P, Schnapp A. Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. The Journal of Pharmacology and Experimental Therapeutics. July 2010. doi:10.1124/jpet.110.167007 · PMID 20371707
5. Other Striverdi Respimat (olodaterol) Inhalation Spray For Oral Inhalation. U.S. Full Prescribing Information
6. Other Austria-Codex. 2009
7. Other Hollis A. Panel Overwhelmingly Supports Boehringer COPD Drug Striverdi. 31 January 2013
8. Other New once-daily Striverdi (olodaterol) Respimat gains approval in first EU countries. 18 October 2013
9. Journal / agency FDA approves Striverdi Respimat to treat chronic obstructive pulmonary disease. 31 July 2014

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.